A	O
Novel	O
Distal	O
Enhancer	O
Mediates	O
Inflammation	O
-	O
,	O
PTH	S-GENE
-	O
,	O
and	O
Early	O
Onset	O
Murine	O
Kidney	O
Disease	O
-	O
Induced	O
Expression	O
of	O
the	O
Mouse	O
Fgf23	S-GENE
Gene	O
.	O
Fibroblast	B-GENE
growth	I-GENE
factor	I-GENE
23	E-GENE
(	O
FGF23	S-GENE
)	O
production	O
is	O
regulated	O
by	O
both	O
calciotropic	O
hormones	O
and	O
inflammation	O
.	O


Consistent	O
with	O
this	O
,	O
elevated	O
FGF23	S-GENE
levels	O
are	O
associated	O
with	O
inflammatory	O
markers	O
as	O
well	O
as	O
parathyroid	B-GENE
hormone	E-GENE
(	O
PTH	S-GENE
)	O
in	O
various	O
disease	O
states	O
,	O
including	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O


However	O
,	O
the	O
molecular	O
mechanisms	O
underpinning	O
Fgf23	S-GENE
transcription	O
in	O
response	O
to	O
these	O
regulators	O
are	O
largely	O
unknown	O
.	O


We	O
therefore	O
utilized	O
chromatin	O
immunoprecipitation	O
followed	O
by	O
DNA	O
sequencing	O
(	O
ChIP	O
-	O
seq	O
)	O
data	O
from	O
an	O
osteocyte	O
cell	O
line	O
to	O
identify	O
potential	O
regulatory	O
regions	O
of	O
the	O
Fgf23	S-GENE
gene	O
.	O


Based	O
on	O
ChIP	O
-	O
seq	O
analysis	O
of	O
enhancer	O
-	O
associated	O
histone	O
modifications	O
,	O
including	O
H3K4	O
methylation	O
and	O
H3K9	O
acetylation	O
,	O
we	O
discovered	O
several	O
potential	O
enhancers	O
for	O
Fgf23	S-GENE
,	O
one	O
of	O
which	O
was	O
located	O
16kb	O
upstream	O
of	O
the	O
gene	O
'	O
s	O
transcriptional	O
start	O
site	O
.	O


Deletion	O
of	O
this	O
putative	O
enhancer	O
from	O
the	O
mouse	O
genome	O
using	O
CRISPR	O
-	O
Cas9	O
technology	O
led	O
to	O
lower	O
bone	O
,	O
thymus	O
,	O
and	O
spleen	O
expression	O
of	O
Fgf23	S-GENE
mRNA	O
without	O
altering	O
circulating	O
levels	O
of	O
the	O
intact	O
hormone	O
,	O
although	O
as	O
previously	O
reported	O
,	O
only	O
bone	O
displayed	O
significant	O
basal	O
expression	O
.	O


Nevertheless	O
,	O
lack	O
of	O
the	O
-	O
16kb	O
enhancer	O
blunted	O
FGF23	S-GENE
upregulation	O
in	O
a	O
tissue	O
-	O
specific	O
manner	O
by	O
the	O
acute	O
inflammatory	O
inducers	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
interleukin	B-GENE
-	I-GENE
1	I-GENE
-	I-GENE
beta	E-GENE
(	O
IL	B-GENE
-	I-GENE
1beta	E-GENE
)	O
,	O
and	O
tumor	B-GENE
necrosis	I-GENE
factor	I-GENE
-	I-GENE
alpha	E-GENE
(	O
TNFalpha	S-GENE
)	O
in	O
bone	O
,	O
non	O
-	O
osseous	O
tissues	O
,	O
and	O
in	O
circulation	O
.	O


Lack	O
of	O
the	O
-	O
16kb	O
enhancer	O
also	O
inhibited	O
PTH	O
-	O
induced	O
bone	O
Fgf23	S-GENE
mRNA	O
.	O


Moreover	O
,	O
the	O
absence	O
of	O
this	O
Fgf23	S-GENE
enhancer	O
in	O
an	O
oxalate	O
diet	O
-	O
induced	O
murine	O
CKD	O
model	O
prevented	O
the	O
early	O
onset	O
induction	O
of	O
osseous	O
,	O
renal	O
,	O
and	O
thymic	O
Fgf23	S-GENE
mRNA	O
levels	O
and	O
led	O
to	O
a	O
significant	O
blunting	O
of	O
elevated	O
circulating	O
intact	O
FGF23	S-GENE
levels	O
.	O


These	O
results	O
suggest	O
that	O
-	O
16kb	O
enhancer	O
mediates	O
the	O
induction	O
of	O
Fgf23	S-GENE
by	O
inflammation	O
and	O
PTH	S-GENE
and	O
facilitates	O
the	O
increase	O
in	O
FGF23	S-GENE
expression	O
in	O
a	O
murine	O
model	O
of	O
CKD	O
.	O


As	O
exemplified	O
herein	O
,	O
these	O
Fgf23	S-GENE
enhancer	O
-	O
deleted	O
mice	O
will	O
provide	O
a	O
unique	O
model	O
in	O
which	O
to	O
study	O
the	O
role	O
of	O
FGF23	S-GENE
expression	O
in	O
inflammatory	O
diseases	O
.	O
